PubMed

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.

Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB; Treatment of Osteoporosis with Parathyroid Hormone Study Group.

Ann Intern Med. 2007 Mar 6;146(5):326-39.PMID: 17339618 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD.

JAMA. 1999 Oct 13;282(14):1344-52.PMID: 10527181 [PubMed - indexed for MEDLINE]Related articlesFree article

Summaries for patients. Parathyroid hormone (1-84) and risk for spinal fractures in women with osteoporosis.

[No authors listed]

Ann Intern Med. 2007 Mar 6;146(5):I20. No abstract available. PMID: 17339614 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.

Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.

J Clin Endocrinol Metab. 1997 Feb;82(2):620-8.PMID: 9024265 [PubMed - indexed for MEDLINE]Related articlesFree article

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR.

JAMA. 1999 Aug 18;282(7):637-45. Erratum in: JAMA 1999 Dec 8;282(22):2124. PMID: 10517716 [PubMed - indexed for MEDLINE]Related articlesFree article

Recombinant full-length parathyroid hormone (1-84).

Moen MD, Scott LJ.

Drugs. 2006;66(18):2371-81; discussion 2382-5. Review.PMID: 17181378 [PubMed - indexed for MEDLINE]Related articles

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.

N Engl J Med. 2001 May 10;344(19):1434-41.PMID: 11346808 [PubMed - indexed for MEDLINE]Related articlesFree article

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.

J Bone Miner Res. 2004 May;19(5):728-36. Epub 2004 Jan 19.PMID: 15068495 [PubMed - indexed for MEDLINE]Related articles

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.

Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F.

Lancet. 1997 Aug 23;350(9077):550-5.PMID: 9284777 [PubMed - indexed for MEDLINE]Related articles

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group.

JAMA. 2006 Dec 27;296(24):2927-38.PMID: 17190893 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).

J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.PMID: 15231010 [PubMed - indexed for MEDLINE]Related articles

WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.

Cranney A, Adachi JD, Guyatt G, Papaioannou A, Robinson VA, Shea BJ, Tugwell P, Waldegger LM, Weaver B, Wells G, Zytaruk N.

Cochrane Database Syst Rev. 2007 Jul 18;(1):CD004523. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD004523. PMID: 17636764 [PubMed - indexed for MEDLINE]Related articles

Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.

Fogelman I, Fordham JN, Fraser WD, Spector TD, Christiansen C, Morris SA, Fox J.

Calcif Tissue Int. 2008 Aug;83(2):85-92. Epub 2008 Jul 15.PMID: 18626566 [PubMed - indexed for MEDLINE]Related articles

Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling.

Black DM, Bouxsein ML, Palermo L, McGowan JA, Newitt DC, Rosen E, Majumdar S, Rosen CJ; PTH Once-Weekly Research (POWR) Group.

J Clin Endocrinol Metab. 2008 Jun;93(6):2166-72. Epub 2008 Mar 18.PMID: 18349061 [PubMed - indexed for MEDLINE]Related articlesFree article

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.

Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY.

N Engl J Med. 2004 Jan 29;350(5):459-68.PMID: 14749454 [PubMed - indexed for MEDLINE]Related articlesFree article

Risedronate for the prevention and treatment of postmenopausal osteoporosis.

Cranney A, Waldegger L, Zytaruk N, Shea B, Weaver B, Papaioannou A, Robinson V, Wells G, Tugwell P, Adachi JD, Guyatt G.

Cochrane Database Syst Rev. 2003;(4):CD004523. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD004523. PMID: 14584020 [PubMed - indexed for MEDLINE]Related articles

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ.

JAMA. 1998 Dec 23-30;280(24):2077-82.PMID: 9875874 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.

Reginster JY, Meurmans L, Zegels B, Rovati LC, Minne HW, Giacovelli G, Taquet AN, Setnikar I, Collette J, Gosset C.

Ann Intern Med. 1998 Jul 1;129(1):1-8.PMID: 9652994 [PubMed - indexed for MEDLINE]Related articlesFree article

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.

Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH.

Arch Intern Med. 2004 Oct 11;164(18):2024-30.PMID: 15477438 [PubMed - indexed for MEDLINE]Related articlesFree article

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.PMID: 12458987 [PubMed - indexed for MEDLINE]Related articlesFree article